



JFW

PATENT  
ATTORNEY DOCKET NO. 50164/033002

Certificate of Mailing: Date of Deposit: January 24, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathy Kirby

Printed name of person mailing correspondence

*Kathy Kirby*

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Edward Roydon Jost-Price et al. Confirmation No.: 6397  
Serial No.: 10/777,518 Art Unit: 1617  
Filed: February 12, 2004 Examiner: Jennifer M. Kim  
Customer No.: 21559  
Title: COMBINATION THERAPY FOR THE TREATMENT OF  
IMMUNOINFLAMMATORY DISORDERS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the abstracts listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of an Office Action from the European patent office in a counterpart application is also enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 1/2-1/07

  
\_\_\_\_\_  
Michael J. Belliveau, Ph.D.  
Reg. No. 52,608

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/033002
		Serial No.	10/777,518
		Applicant	Roydon Jost-Price et al.
		Filing Date	February 12, 2004
		Group	1617
		IDS Filed	January 24, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Chuong et al., "In vitro and in vivo Immunosuppressive Potential of Thalidomide and its Derivative, N-Hydroxythalidomide, Alone and in Combination with Cyclosporin A," <i>Int. J. Immunopharmacol.</i> 19:289 (1997) Abstract only.
	D'Ambrosio et al., "The Modulatory Effect of Diltiazem on Human <i>In Vitro</i> Alloreactivity When Used Alone or in Combination with Cyclosporin A and/or Methylprednisolone," <i>Transpl. Int.</i> 10:426 (1997) Abstract only.
	Giovanna et al., "Combination Therapy with Cyclosporine and Methotrexate in Refractory Rheumatoid Arthritis," <i>Recenti Progressi in Medicina</i> 89:7 (1998) Abstract only.
	Matuura et al., "Suppression of Experimental Autoimmune Uveoretinitis With a Combination of Cyclosporin and Allopurinol," <i>Nippon Ganka Gakkai Zasshi.</i> 103:26 (1999) Abstract only.
	European Application No. 04 710 606.7-1521 Office Action- October 23, 2006

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	